Merrimack Pharmaceuticals (NASDAQ:MACK) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1.5 by 4 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Baird initiates coverage on Merrimack Pharmaceuticals (NASDAQ:MACK). The current rating of the shares is Neutral, according to the research report released by the firm. The rating by the firm was issued on May 26, 2016.
Merrimack Pharmaceuticals (NASDAQ:MACK): According to 2 Analysts, The short term target price has been estimated at $ 12.The target price could deviate by a maximum of $5.66 from the forecast price. In the near term, the target price could hit a high of $16 and a low of $ 8.
Merrimack Pharmaceuticals (NASDAQ:MACK) witnessed a decline in the market cap on Tuesday as its shares dropped 1.56% or 0.1 points. After the session commenced at $6.4, the stock reached the higher end at $6.4 while it hit a low of $6.15. With the volume soaring to 1,548,213 shares, the last trade was called at $6.29. The company has a 52-week high of $13. The company has a market cap of $803 million and there are 127,725,130 shares in outstanding. The 52-week low of the share price is $5.02.
Shares of Merrimack Pharmaceuticals, Inc. appreciated by 1.13% during the last five trading days but lost 3.82% on a 4-week basis. Merrimack Pharmaceuticals, Inc. has dropped 28.11% during the last 3-month period . Year-to-Date the stock performance stands at -20.38%.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Companys most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.